Liposomal Paclitaxel Market Size, Share and Trends Analysis Report, By Application (Breast Cancer, Lungs Cancer, Ovarian Cancer, and Others), Forecast (2022-2028)

The global liposomal paclitaxel market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Liposomal paclitaxel is a new formulation of the anti-cancer agent paclitaxel for injection or taxane used to treat a broad range of cancers. Paclitaxel helps to prevent cells from dividing and growing, resulting in cell death. The global market is growing due to the increasing prevalence of cancer patients globally. According to National Cancer Statistics 2020, an estimation of 1,806,590 new cases of cancer were diagnosed in the US alone and 606,520 people died from the disease. Breast cancer and lungs cancer are the highest prevalent type of cancer in the US. The source also states that cancer is considered the leading cause of death globally. According to the WHO, 19.3 million new cancer cases were registered and 9.9 million deaths were registered globally in 2020. Therefore, the increasing prevalence of cancer patients globally and the adoption of new advanced technologies for the treatment of this disease are driving the growth of the global liposomal paclitaxel market.

The market players are also contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new drug launches, to stay competitive in the market. For instance-

• In February 2021, USFDAapproved oral paclitaxel as the first oral taxane, a novel alternative to standard IV chemotherapy, to elicit a higher overall response rate than Pac.
• In September 2020, Athenex, Inc. receivedUSFDA approval for oral paclitaxel and encequidar oral paclitaxel for the treatment of metastatic breast cancer.
• In April 2020, F. Hoffmann-La Roche Ltd. received Drugs Controller General of India’sapproval for Atezolizumab in combination with nab-Paclitaxel for the treatment of metastatic triple-negative breast cancer in India.
• In March 2019, the European Medicines Agency’s Committee for medicinal products for human use adopted a positive opinion, recommending the granting of the medicinal product Pazenir, for the treatment of metastatic breast cancer and non-small cell lung cancer.
• In March 2019, Bristol-Myers Squibb Co. announced their international Phase 3 study update on accelerated approval of TECENTRIQ atezolizumab in combination with nab-Paclitaxel and ABRAXANE for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer.

Market Coverage

• The market number available for – 2022-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape-Luye Pharma Group and CSPC Pharmaceutical Group Ltd.,among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Liposomal Paclitaxel Market Report by Segment

By Application

• Breast Cancer
• Lungs Cancer
• Ovarian Cancer
• Others

Global Liposomal Paclitaxel Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa